InsiderDB

Lobbying disclosures · Lobbying report

LLY: third_quarter 2026 lobbying report

Issues related to the pharmaceutical industry Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain

Follow LLY
Became public
Oct 16, 2026, 7:21 PM EDT
Event / period date
Not stated
Collected
Nov 11, 2026, 5:07 AM EST

Why this is connected

Legal-name match: ELI LILLY AND COMPANY is ELI LILLY & Co (https://www.sec.gov/Archives/edgar/data/59478/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).

Reported lobbying amounts

Income: $90,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/18478f49-aedf-42e6-8e5a-37ceddb7ba29/","filing_uuid":"18478f49-aedf-42e6-8e5a-37ceddb7ba29","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/18478f49-aedf-42e6-8e5a-37ceddb7ba29/print/","filing_document_content_type":"text/html","income":"90000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"William Moschella, Attorney at Law","dt_posted":"2026-10-16T19:21:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"600 Massachusetts Ave, NW","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":7257,"url":"https://lda.gov/api/v1/registrants/7257/","house_registrant_id":31842,"name":"BROWNSTEIN HYATT FARBER SCHRECK, LLP","description":"Law firm","address_1":"600 Massachusetts Ave, NW","address_2":"Suite 400","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"QUINN MCKAY","contact_telephone":"+1 202-872-5292","dt_updated":"2026-07-30T12:03:37.302760-04:00"},"client":{"id":110341,"url":"https://lda.gov/api/v1/clients/110341/","client_id":1009420,"name":"ELI LILLY AND COMPANY","general_description":"Pharmaceuticals","client_government_entity":false,"client_self_select":null,"state":"IN","state_display":"Indiana","country":"US","country_display":"United States of America","ppb_state":"IN","ppb_state_display":"Indiana","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-10-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to the pharmaceutical industry Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":61089,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"PFISTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70425,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"FELDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":103206,"prefix":null,"prefix_display":null,"first_name":"ADAM","nickname":null,"middle_name":null,"last_name":"STEINMETZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143000,"prefix":null,"prefix_display":null,"first_name":"DEEMA","nickname":null,"middle_name":null,"last_name":"TARAZI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142877,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"SUNSTRUM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151303,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":155383,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"PHILLIPS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":155119,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"MORSE","suffix":null,"suffix_display":null},"covered_position":"Principal Deputy Assistant Secretary for Legislation at the Department of Health and Human Services; Deputy Assistant Secretary for Legislation at the Department of Health and Human Services","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143188,"prefix":null,"prefix_display":null,"first_name":"BRANDT","nickname":null,"middle_name":null,"last_name":"ANDERSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":103206,"prefix":null,"prefix_display":null,"first_name":"ADAM","nickname":null,"middle_name":null,"last_name":"STEINMETZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61089,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"PFISTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70425,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"FELDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151303,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in LLY

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.